NewEdge Advisors LLC Has $33,000 Stake in DaVita Inc. $DVA

NewEdge Advisors LLC reduced its stake in shares of DaVita Inc. (NYSE:DVA) by 96.9% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 217 shares of the company’s stock after selling 6,686 shares during the quarter. NewEdge Advisors LLC’s holdings in DaVita were worth $33,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Invesco Ltd. boosted its stake in DaVita by 2.0% during the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after acquiring an additional 32,358 shares during the last quarter. Morgan Stanley increased its stake in DaVita by 5.1% in the fourth quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock valued at $167,807,000 after purchasing an additional 71,156 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after purchasing an additional 636,191 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in DaVita by 5.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock worth $176,037,000 after purchasing an additional 56,336 shares during the period. Finally, LSV Asset Management boosted its position in shares of DaVita by 1.1% during the fourth quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after purchasing an additional 9,739 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

DVA opened at $178.70 on Friday. The company has a market capitalization of $11.40 billion, a price-to-earnings ratio of 14.62, a P/E/G ratio of 0.60 and a beta of 0.88. The business’s 50-day moving average price is $212.49 and its two-hundred day moving average price is $183.06. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.DaVita’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the company earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts anticipate that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DVA. Barclays upped their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $265.00 target price on shares of DaVita in a research note on Wednesday, August 5th. Raymond James Financial set a $220.00 price target on DaVita in a research report on Friday, August 7th. Oppenheimer set a $220.00 price objective on DaVita in a report on Friday, August 7th. Finally, UBS Group increased their target price on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $221.75.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.